PDS Biotechnology Corporation Common Stock PDSB
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-07T06:24:58.538Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-13
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-07T00:57:11.747905848Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-07T06:16:55.077726+00:00
PDS Biotechnology Corporation Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 1.01 | 271.1% | 23.6% | |||
| 30Δ | 1.06 | 260.4% | 21.7% | |||
| 35Δ | 1.10 | 249.8% | 19.8% | |||
| 40Δ | 2.87 | 800.0% | 165.9% | 1.14 | 239.1% | 17.8% |
| 45Δ | 2.49 | 800.0% | 135.1% | 1.18 | 228.4% | 15.9% |
| 50Δ | 2.19 | 800.0% | 110.2% | 1.23 | 217.7% | 14.0% |
| 55Δ | 1.27 | 207.0% | 12.1% | |||
| 60Δ | 1.31 | 196.4% | 10.2% | |||
| 65Δ | 1.35 | 185.7% | 8.3% | |||
| 70Δ | ||||||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.01
- IV
- 271.1%
- B/E move
- 23.6%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.06
- IV
- 260.4%
- B/E move
- 21.7%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.10
- IV
- 249.8%
- B/E move
- 19.8%
40Δ
- Pseudo strike
- 2.87
- IV
- 800.0%
- B/E move
- 165.9%
- Pseudo strike
- 1.14
- IV
- 239.1%
- B/E move
- 17.8%
45Δ
- Pseudo strike
- 2.49
- IV
- 800.0%
- B/E move
- 135.1%
- Pseudo strike
- 1.18
- IV
- 228.4%
- B/E move
- 15.9%
50Δ
- Pseudo strike
- 2.19
- IV
- 800.0%
- B/E move
- 110.2%
- Pseudo strike
- 1.23
- IV
- 217.7%
- B/E move
- 14.0%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.27
- IV
- 207.0%
- B/E move
- 12.1%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.31
- IV
- 196.4%
- B/E move
- 10.2%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.35
- IV
- 185.7%
- B/E move
- 8.3%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 257.17% | |
| 178.87% | |
| 214.16% | |
| 258.37% | |
| 304.13% | |
| 367.57% | |
| 357.78% | |
| 312.99% |
Biotechnology
PEPG
PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious neurological and…
More →PGEN
Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
More →PHAT
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is…
More →PHVS
Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies. The company is headquartered in Leiden, the…
More →PLX
Description unavailable
More →PRAX
Description unavailable
More →